在甲状旁腺功能亢进症中加用SPECT/CT于减影甲状旁腺显像:在以终末期肾病患者为主的队列中的诊断效能
该回顾性研究以病理结果为参考标准,在116例患者(其中98例84.5%为终末期肾病)中比较了[99mTc]NaTcO4/[99mTc]Tc-MIBI平面减影甲状旁腺显像、SPECT/CT及两者联合的诊断效能。结果显示,在终末期肾病患者中SPECT/CT并不优于减影显像;联合判读可提高灵敏度,但可能以降低特异度为代价。
要点
- 在终末期肾病患者中,减影显像、SPECT/CT及联合判读的灵敏度分别为69%、67%和79%,特异度分别为68%、71%和60%。
- 在非终末期肾病患者中,减影显像、SPECT/CT及联合判读的灵敏度分别为93%、89%和100%,特异度分别为88%、87%和84%。
- 在终末期肾病患者中,联合判读较减影显像提高灵敏度,但特异度降低。
核心结论
- 在终末期肾病合并甲状旁腺功能亢进症患者中,SPECT/CT并不优于减影甲状旁腺显像。
- 联合两种技术可提高灵敏度,但可能以降低特异度为代价。
- 与非终末期肾病患者相比,减影显像和SPECT/CT在终末期肾病患者中的诊断效能均欠佳。
研究设计与样本
- 回顾性研究,共纳入116例患者,其中98例(84.5%)为终末期肾病。
- 以组织病理学结果为参考标准,比较[99mTc]NaTcO4/[99mTc]Tc-MIBI平面减影甲状旁腺显像、SPECT/CT及两者联合判读的诊断效能。
主要发现
- 总体灵敏度:减影显像69%(95%CI 64-73%),SPECT/CT 67%(61-72%),联合判读79%(74-84%)。
- 总体特异度:减影显像68%(59-76%),SPECT/CT 71%(61-80%),联合判读60%(50-70%)。
- 非终末期肾病患者灵敏度:减影显像93%(70-99%),SPECT/CT 89%(57-98%),联合判读100%(70-100%)。
- 非终末期肾病患者特异度:减影显像88%(76-94%),SPECT/CT 87%(71-95%),联合判读84%(67-93%)。
- 终末期肾病患者灵敏度:减影显像67%(62-72%),SPECT/CT 66%(60-71%),联合判读78%(73-83%);特异度分别为55%(42-67%)、57%(43-70%)、43%(30-58%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SPECT/CT has been well established as a valuable technique in nuclear medicine parathyroid imaging, but most previous studies were done in patients with primary hyperparathyroidism. In this retrospective study, we examined the diagnostic performance of [99mTc]NaTcO4 / [99mTc]Tc-MIBI planar subtraction parathyroid scintigraphy (PS), SPECT/CT, and a combination of the two in a patient cohort consisting of mostly end-stage renal disease (ESRD) patients with secondary or tertiary hyperparathyroidism, using histopathological results as the reference standard. RESULTS: Among 116 patients included, 98 (84.5%) had ESRD. The overall sensitivity of subtraction PS, SPECT/CT and combined interpretation was 69% (95% confidence interval: 64-73%), 67% (61-72%), and 79% (74-84%), while the specificity was 68% (59-76%), 71% (61-80%), and 60% (50-70%), respectively. For patients without ESRD with predominantly primary hyperparathyroidism, the sensitivity was 93% (70-99%), 89% (57-98%), and 100% (70-100%), and the specificity was 88% (76-94%), 87% (71-95%), and 84% (67-93%), respectively. For those with ESRD with predominantly tertiary and secondary hyperparathyroidism, the sensitivity was 67% (62-72%), 66% (60-71%), 78% (73-83%), and the specificity was 55% (42-67%), 57% (43-70%), and 43% (30-58%), respectively. CONCLUSION: SPECT/CT was not superior to subtraction PS in ESRD patients with hyperparathyroidism. Combining these two techniques improves sensitivity, but likely with the expense of reduction in specificity. Both planar subtraction PS and SPECT/CT have suboptimal diagnostic performance in ESRD patients compared with non-ESRD patients where these techniques provide impressive sensitivity and specificity.
引用
- Jitrapinate W, Raruenrom Y, Wongsurawat N, et al. SPECT/CT in addition to subtraction parathyroid scintigraphy in hyperparathyroidism: diagnostic performance in a cohort of predominantly end-stage renal disease patients. EJNMMI Res. 2025. PMID: 40186673. doi:10.1186/s13550-025-01234-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。